Loading...
Market
What will be the primary outcome of the TuftsLyme study by end of 2025?
2
Resolution / Starting Odds
Identification of new biomarkers • 25%
Development of new treatment protocols • 25%
Discovery of new disease pathways • 25%
No significant findings • 25%
Publication or official press release by Tufts School of Medicine or NIH
Story
TUSM Researchers Secure $20.7M NIH Grant for Largest Chronic Lyme Disease Study
Sep 17, 2024, 06:16 PM
Researchers at Tufts School of Medicine (TUSM), led by Dr. Linden Hu, have secured a $20.7 million grant from the National Institutes of Health (NIH) to study chronic Lyme disease. This is the largest NIH-backed study to date aimed at understanding the long-term symptoms of the disease. The study, involving TuftsLyme, seeks to unlock the mysteries behind the chronic conditions experienced by patients.
View original story
Similar markets
Yes • 50%
No • 50%
New treatments • 25%
Diagnostic tools • 25%
Vaccine development • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful completion of Phase 1 • 25%
Partial success in Phase 1 • 25%
Failure in Phase 1 • 25%
No results announced • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Persistent viral RNA • 25%
T cell activation • 25%
Chronic inflammation • 25%
Other • 25%
High efficacy • 25%
Moderate efficacy • 25%
Low efficacy • 25%
No significant efficacy • 25%
United States • 25%
Germany • 25%
United Kingdom • 25%
Other • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%
Brain Fog • 25%
Fatigue • 25%
Inflammation • 25%
Other • 25%